Please login to the form below

Not currently logged in
Email:
Password:

RNAi

This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

That includes pairing Regeneron's phase 1 antibody pozelimab (REGN3918) with Alnylam’s phase 2 RNAi drug cemdisiran, both of which target the complement C5 pathway, including other antibody/RNAi combinations. ... parties. It also reinforces the

Latest news

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    Genzyme had previously licensed rights in 2012 to Alnylam’s lead RNAI drug Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), which became the first drug in the RNAi class ... The R&D deal was tweaked in January

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    Other highlights of the year included Alnylam’s hereditary ATTR amyloidosis drug Onpattro (patisiran) becaming the first RNA interference (RNAi) therapy to get a green light from the FDA.

  • NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

    Gaining NICE recommendation would be a major milestone for both companies – Onpattro is Alnylam’s debut product from its RNA interference (RNAi) drug platform, while Tegsedi is similarly Akcea’s first

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Bolsters pipeline ahead of Soliris patent protection loss. Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases. ... In return, Alexion will have access to Dicerna’s GalXC technology, which is

  • Alnylam seeks fast-track filing with biomarker data Alnylam seeks fast-track filing with biomarker data

    Early filing reflects FDA desire for faster approvals. Alnylam is set to file its next RNAi drug candidate givosiran with regulators after producing strong phase 3 data. ... After 15 years building its RNAi ‘gene silencing’ platform, the Cambridge,

More from news
Approximately 7 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.

  • Deal Watch September 2016 Deal Watch September 2016

    800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's

  • Pharma deals during January 2014 Pharma deals during January 2014

    The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies. ... The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics